Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).

NCT07671417 is registered in ClinicalTrials.gov with RayzeBio, Inc. as lead sponsor.

NCT NCT07671417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).
Lead sponsor
RayzeBio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 15, 2026
Completion date
February 28, 2027
Enrollment
10 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal cell carcinoma